{"entity":{"id":"axcynsis-therapeutics","kind":"company","name":"Axcynsis Therapeutics","aka":["Axcynsis Therapeutics Pte Ltd","Tetris Therapeutics"],"tldr":"Axcynsis Therapeutics makes antibody-drug conjugates, antibodies that carry a cell-killing drug to cancer cells; its first one, aimed at the protein CLDN6, is in an early trial in advanced solid tumours.","summary":"Axcynsis Therapeutics Pte Ltd is a Singapore antibody-drug conjugate company with a Shanghai office. It was established in March 2022 as Tetris Therapeutics, according to the company, and later renamed. Its platform includes the AxcynDOT payload technology. AT03-65, a CLDN6-targeting ADC and the first programme on AxcynDOT, received FDA IND clearance in January 2025 and began a first-in-human phase 1 trial in the United States in advanced CLDN6-positive solid tumours, announced in February 2026 (NCT06809114). Preclinical programmes include a DLL3 by SEZ6 bispecific ADC for small cell lung cancer, a dual-payload ROR1 ADC, a HER2 ADC and an ALPP/ALPPL2 ADC. In May 2022, as Tetris Therapeutics, it raised USD 15 million in seed funding. Its first registered cancer trial, NCT06809114, was posted on ClinicalTrials.gov in February 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://axcynsis.com/"},{"label":"Pipeline","url":"https://axcynsis.com/pipeline/"},{"label":"Phase 1 start release, February 2026","url":"https://axcynsis.com/phase-1-clinical-trial/"},{"label":"ClinicalTrials.gov: phase 1 trial of AT03-65 (NCT06809114)","url":"https://clinicaltrials.gov/study/NCT06809114"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc","bispecific-adc","dual-payload-adc"],"targets":["cldn6","dll3","ror1","her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding date and seed round from the company's May 2022 release; pipeline and phase 1 start from the company's pipeline page and February 2026 release, read on 29 October 2026."],"hq":"Singapore","country":"SG","companyType":"biotech","website":"https://axcynsis.com/","founded":2022,"stage":"startup","investors":[],"funding":[{"round":"Seed","year":2022,"amountUsd":15000000,"source":"https://axcynsis.com/tetris-therapeutics-raises-us15-million-in-seed-funding-to-revolutionize-targeted-cancer-treatments/","note":"Raised as Tetris Therapeutics"}]},"route":"/companies/axcynsis-therapeutics/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/"}],"target":[{"id":"cldn6","kind":"target","name":"Claudin 6","route":"/targets/cldn6/"},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"ror1","kind":"target","name":"ROR1","route":"/targets/ror1/"}]}}